A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Prior treatment

• Major surgery within 4 weeks of random assignment
• Diagnosed or treated for malignancy other than MCL, except: malignancy treated with curative intent and with no known active disease present for \>=3 years before random assignment; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease
• Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
• History of stroke or intracranial hemorrhage within 6 months prior to random assignment
• Requires treatment with strong CYP3A inhibitors
• Vaccinated with live, attenuated vaccines within 4 weeks of random assignment

Other illness

• Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
• Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
• Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk

Other

• Known central nervous system lymphoma
• Requires anticoagulation with warfarin or equivalent vitamin K antagonists

• Diagnosis of mantle cell lymphoma (MCL) reviewed and approved by central laboratory: diagnosis must include morphology and expression of either cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5 and CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)
• Clinical Stage II, III, or IV by Ann Arbor Classification
• At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
• No prior therapies for MCL
• Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or 1
• Hematology and biochemical laboratory values within protocol-defined limits
• Agrees to protocol-defined use of effective contraception
• Negative blood or urine pregnancy test at screening